Tammie Benzinger

Radiology Washington University, Saint Louis, St. Louis, MO 
"Tammie Benzinger"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Iaccarino L, Llibre-Guerra JJ, McDade E, et al. (2024) Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease. Brain Communications. 6: fcae159
Earnest T, Bani A, Ha SM, et al. (2024) Data-driven decomposition and staging of flortaucipir uptake in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Wagemann O, Liu H, Wang G, et al. (2024) Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. Jama Neurology
Wisch JK, McKay NS, Boerwinkle AH, et al. (2024) Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study. The Lancet. Neurology. 23: 500-510
McKay NS, Millar PR, Nicosia J, et al. (2024) Pick a PACC: Comparing domain-specific and general cognitive composites in Alzheimer disease research. Neuropsychology
Doering S, McCullough A, Gordon BA, et al. (2024) Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimaging. Ebiomedicine. 103: 105080
Salvadó G, Horie K, Barthélemy NR, et al. (2024) Disease staging of Alzheimer's disease using a CSF-based biomarker model. Nature Aging
Meeker KL, Luckett PH, Barthélemy NR, et al. (2024) Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer's disease. Brain Communications. 6: fcae081
Li Y, Yen D, Hendrix RD, et al. (2024) Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset. Annals of Neurology
Wang G, Li Y, Xiong C, et al. (2024) Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association
See more...